Maureen Ann McGargill

Maureen Ann McGargill

Auto-generated profile, based on publicly available information

Maureen Ann McGargill

Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN, USA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 April 2022 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
AMAnastasia A. Minervina
Anastasia A. Minervina
MPMikhail V. Pogorelyy
Mikhail V. Pogorelyy
AKAllison M. Kirk
Allison M. Kirk
JCJeremy Chase Crawford
Jeremy Chase Crawford
EAE. Kaitlynn Allen
E. Kaitlynn Allen
PTPaul G Thomas
Paul G Thomas

20 October 2013 in Nature Immunology
Verified
Journal Article
Open access
PDF file
RKRachael Keating
Rachael Keating
THTomer Hertz
Tomer Hertz
MWMarie Wehenkel
Marie Wehenkel
THTarsha L Harris
Tarsha L Harris
BEBenjamin A Edwards
Benjamin A Edwards
MMMaureen A McGargill
Maureen A McGargill
Influenza viruses are highly variable, which complicates vaccine strategies to protect against emerging viruses. McGargill and colleagues show that blocking the mTORC1 complex skews antibody responses to more conserved epitopes, thereby producing heterosubtypic protection. Highly pathogenic avian influenza viruses pose a continuing global threat. Current vaccines will not protect against newly evolved pandemic viruses. The creation of 'universal' vaccines has been unsuccessful because the immunological mechanisms that promote heterosubtypic immunity are incompletely defined. We found here that rapamycin, an immunosuppressive drug that inhibits the kinase mTOR, promoted cross-strain protection against lethal infection with influenza virus of various subtypes when administered during immunization with influenza virus subtype H3N2. Rapamycin reduced the formation of germinal centers and inhibited class switching in B cells, which yielded a unique repertoire of antibodies that mediated heterosubtypic protection. Our data established a requirement for the mTORC1 complex in B cell class switching and demonstrated that rapamycin skewed the antibody response away from high-affinity variant epitopes and targeted more conserved elements of hemagglutinin. Our findings have implications for the design of a vaccine against influenza virus.

7 December 2021 in Cell Host & Microbe
Verified
Journal Article
Open access
CLChun-Yang Lin
Chun-Yang Lin
JWJoshua Wolf
Joshua Wolf
DBDavid C. Brice
David C. Brice
YSYilun Sun
Yilun Sun
MLMacauley Locke
Macauley Locke
MMMaureen A. McGargill
Maureen A. McGargill
SARS-CoV-2 infection causes diverse outcomes ranging from asymptomatic infection to respiratory distress and death. A major unresolved question is whether prior immunity to endemic, human common cold coronaviruses (hCCCoVs) impacts susceptibility to SARS-CoV-2 infection or immunity following infection and vaccination. Therefore, we analyzed samples from the same individuals before and after SARS-CoV-2 infection or vaccination. We found hCCCoV antibody levels increase after SARS-CoV-2 exposure, demonstrating cross-reactivity. However, a case-control study indicates that baseline hCCCoV antibody levels are not associated with protection against SARS-CoV-2 infection. Rather, higher magnitudes of pre-existing betacoronavirus antibodies correlate with more SARS-CoV-2 antibodies following infection, an indicator of greater disease severity. Additionally, immunization with hCCCoV spike proteins before SARS-CoV-2 immunization impedes the generation of SARS-CoV-2-neutralizing antibodies in mice. Together, these data suggest that pre-existing hCCCoV antibodies hinder SARS-CoV-2 antibody-based immunity following infection and provide insight on how pre-existing coronavirus immunity impacts SARS-CoV-2 infection, which is critical considering emerging variants.

11 May 2016 in Frontiers in Immunology
Verified
Journal Article
Open access
RKRachael Keating
Rachael Keating
MMMaureen Ann McGargill
Maureen Ann McGargill
Immunity to pathogens exists as a fine balance between promoting activation and expansion of effector cells, while simultaneously limiting normal and aberrant responses. These seemingly opposing functions are kept in check by immune regulators. The mechanistic target of rapamycin (mTOR) is a serine/threonine kinase that senses nutrient availability and in turn, regulates cell metabolism, growth, and survival accordingly. mTOR plays a pivotal role in facilitating immune defense against invading pathogens by regulating the differentiation, activation, and effector functions of lymphoid cells. Here we focus on the emerging and sometimes contradictory roles of mTOR in orchestrating lymphoid cell-mediated host immune responses to pathogens. A thorough understanding of how mTOR impacts lymphoid cells in pathogen defense will provide the necessary base for developing therapeutic interventions for infectious diseases.

29 July 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
THTomer Hertz
Tomer Hertz
SLShlomia Levy
Shlomia Levy
DODaniel Ostrovsky
Daniel Ostrovsky
HOHanna Oppenheimer
Hanna Oppenheimer
SZShosh Zismanov
Shosh Zismanov
OWOrly Weinstein
Orly Weinstein
Vaccination, especially with multiple doses, provides substantial population-level protection against COVID-19, but emerging variants of concern (VOC) and waning immunity represent significant risks at the individual level. Here we identify correlates of protection (COP) in a multicenter prospective study following 607 healthy individuals who received three doses of the Pfizer-BNT162b2 vaccine approximately six months prior to enrollment. We compared 242 individuals who received a fourth dose to 365 who did not. Within 90 days of enrollment, 239 individuals contracted COVID-19, 45% of the 3-dose group and 30% of the four-dose group. The fourth dose elicited a significant rise in antibody binding and neutralizing titers against multiple VOCs reducing the risk of symptomatic infection by 37% [95%CI, 15%-54%]. However, a group of individuals, characterized by low baseline titers of binding antibodies, remained susceptible to infection despite significantly increased neutralizing antibody titers upon boosting. A combination of reduced IgG levels to RBD mutants and reduced VOC-recognizing IgA antibodies represented the strongest COP in both the 3-dose group (HR = 6.34, p = 0.008) and four-dose group (HR = 8.14, p = 0.018). We validated our findings in an independent second cohort. In summary combination IgA and IgG baseline binding antibody levels may identify individuals most at risk from future infections.

26 October 2020 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
SRSvetlana Rezinciuc
Svetlana Rezinciuc
LBLavanya Bezavada
Lavanya Bezavada
ABAzadeh Bahadoran
Azadeh Bahadoran
SDSusu Duan
Susu Duan
RWRuoning Wang
Ruoning Wang
Heather SmallwoodHeather Smallwood
Heather Smallwood
Infection with the influenza virus triggers an innate immune response that initiates the adaptive response to halt viral replication and spread. However, the metabolic response fueling the molecular mechanisms underlying changes in innate immune cell homeostasis remain undefined. Although influenza increases parasitized cell metabolism, it does not productively replicate in dendritic cells. To dissect these mechanisms, we compared the metabolism of dendritic cells to that of those infected with active and inactive influenza A virus and those treated with toll-like receptor agonists. Using quantitative mass spectrometry, pulse chase substrate utilization assays and metabolic flux measurements, we found global metabolic changes in dendritic cells 17 hours post infection, including significant changes in carbon commitment via glycolysis and glutaminolysis, as well as mitochondrial respiration. Influenza infection of dendritic cells led to a metabolic phenotype distinct from that induced by TLR agonists, with significant resilience in terms of metabolic plasticity. We identified c-Myc as one transcription factor modulating this response. Restriction of c-Myc activity or mitochondrial substrates significantly changed the immune functions of dendritic cells, such as reducing motility and T cell activation. Transcriptome analysis of inflammatory dendritic cells isolated following influenza infection showed similar metabolic reprogramming occursin vivo. Thus, early in the infection process, dendritic cells respond with global metabolic restructuring, that is present in inflammatory lung dendritic cells after infection, and this is important for effector function. These findings suggest metabolic switching in dendritic cells plays a vital role in initiating the immune response to influenza infection.